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Abstract
Aims Heart failure with preserved ejection fraction (HFpEF) accounts for half of all heart failure (HF), but low awareness and
diagnostic challenges hinder identification in primary care. Our aims were to evaluate the recruitment and diagnostic strategy
in the Optimise HFpEF cohort and compare with recent recommendations for diagnosing HFpEF.
Methods and results Patients were recruited from 30 primary care practices in two regions in England using an electronic
screening algorithm and two secondary care sites. Baseline assessment collected clinical and patient-reported data and
diagnosis by history, assessment, and trans-thoracic echocardiogram (TTE). A retrospective evaluation compared study
diagnosis with H2FPEF score and HFA-PEFF diagnostic algorithm. A total of 152 patients (86% primary care, mean age 78.5,
40% female) were enrolled; 93 (61%) had HFpEF confirmed. Most participants had clinical features of HFpEF, but those with
confirmed HFpEF were more likely female, obese, functionally impaired, and symptomatic. Some echocardiographic findings
were diagnostic for HFpEF, but no difference in natriuretic peptide levels were observed. The H2FPEF and HFA-PEFF scores
were not significantly different by group, although confirmed HFpEF cases were more likely to have scores indicating high
probability of HFpEF.
Conclusions Patients with HFpEF in primary care are difficult to identify, and greater awareness of the condition, with clear
diagnostic pathways and specialist support, are needed. Use of diagnostic algorithms and scores can provide systematic
approaches to diagnosis but may be challenging to apply in older multi-morbid patients. Where diagnostic uncertainty
remains, pragmatic decisions are needed regarding the value of additional testing versus management of presumptive HFpEF.
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Introduction
Heart failure with preserved ejection fraction (HFpEF) is a
heterogeneous syndrome estimated to account for half of
all heart failure (HF) cases, and the majority of HF in those
aged over 65 years.1 In the United Kingdom (UK), HFpEF
receives relatively little focus in comparison with heart failure
with reduced ejection fraction (HFrEF).2,3 This is despite
predictions that HFpEF will become the dominant form of
HF by virtue of our ageing, multi-morbid population, the rise
of lifestyle-related disease, and improved post-cardiac event
survival.4,5 A recent analysis of 6144 patients referred from
the community with suspected HF and N-terminal pro-brain
natriuretic peptide (NT-proBNP) ≥ 400 pg/mL found that
HFpEF was the most prevalent diagnosis among those
confirmed with HF (46% HFpEF, 40% HFrEF, 13% other).6
However, some specialist centres do not accept referrals for
patients with suspected or confirmed HFpEF and bespoke
clinical services are rare, prompting concern over quality
and sustainability.7,8
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A diagnosis of HFpEF is difficult to establish and may not be
suspected or recognized by clinicians especially in primary
care.9,10 There are variations in diagnostic pathways and a lack
of relevant information in primary care records.11–13 In
addition to impeding appropriate management, lack of
relevant information explicitly identifying HFpEF in patients’
clinical records12 can hamper recruitment to studies,
necessitating the use of confirmatory diagnostic evaluation.
Few studies describe in detail the challenges of recruiting
and confirming a diagnosis in patients with suspected HFpEF
recruited in the community. Such descriptions are important
for informing development of diagnostic pathways that are
relevant to all patients and not selected sub-populations.
The ‘Optimising Management of Patients with Heart
Failure with Preserved Ejection Fraction in Primary Care’
(Optimise HFpEF) cohort study identified and phenotyped
patients with HFpEF in primary care through diagnostic eval-
uation and assessment of comorbidities, functional capacity,
symptoms, and quality of life.14 The aims of this analysis
are to evaluate the recruitment and diagnostic strategy used
and to compare this with recent recommendations for diag-
nosing HFpEF.
Methods
Study design and setting
The full protocol for the Optimise HFpEF programme has been
previously published.14 The study included a Patient Advisory
Group, and patients were involved from before the study
started. In summary, the Optimise HFpEF cohort study was
conducted in the Cambridgeshire and Oxfordshire/Thames
Valley regions. The study was approved by the London–Surrey
Research Ethics Committee in 2017 (REC reference: 17/LO/
2136) and conforms to the standards of the Declaration of
Helsinki. The National Institute for Health Research Clinical
Research Networks (NIHR CRN) facilitated access to general
practices. Practices that agreed to participate in the study
were provided with an electronic medical record screening
algorithm to identify potential HFpEF patients. To simplify
the screening process and increase yield, the automated
search was run within each practice’s existing HF register.
The algorithm was programmed to exclude patients with
Read codes (a coded thesaurus of clinical terms) for left ven-
tricular systolic dysfunction (LVSD) or cardiomyopathy, and a
general practitioner (GP) screened outputs against study in-
clusion/exclusion criteria. Eligible patients were posted an in-
vitation to participate along with study material and asked to
return an expression of interest form. Participants attended a
baseline assessment within designated clinical research facil-
ities or research clinic space. Informed consent was obtained
then participants provided detailed medical information,
completed questionnaires, and underwent assessment. Two
specialist secondary care outpatient services (an HF service
in Peterborough and an older persons’ clinic in London) were
later added due to slow recruitment and a high percentage of
subjects not meeting HFpEF diagnostic criteria.
Sample size
The target sample size was 200 based on the need for an
adequate number of patients to confidently determine prev-
alence of symptoms, signs, and characteristics of patients
with HFpEF in primary care, while considering practical con-
straints of recruiting from this setting. Exemplar analyses in
Stata indicated that in a sample of 200 people, the 95%
confidence interval for an estimate of 10% prevalence of a
specific characteristic in the HFpEF population would be from
6% to 15%. Thus, the sample would have a high degree of
precision to determine the prevalence of specific characteris-
tics such as comorbid conditions, geriatric syndromes, and
findings from diagnostic tests. From a previous study, we
expected that 40% of patients on the HF registers would be
suspected HFpEF.12 Although we estimated that 25% of
recruited patients would not have HFpEF confirmed,15 our
initial intent was to describe the characteristics of patients
with HFpEF including their diagnostic features. Challenges in
recruitment and diagnosis prompted an evaluation of the
process and consideration of more recent recommendations
in diagnosis.
Participants
The target population was people with an existing diagnosis
of HFpEF. However, studies have shown primary care records
hold incomplete information on HF, preventing easy and
accurate identification of patients with HFpEF, and Read
codes specific for HFpEF are rarely used.12,13 GPs were asked
to include patients where there was evidence of non-valvular
HF and a left ventricular ejection fraction (EF) ≥ 50%. Exclu-
sion criteria related both to factors excluding a diagnosis of
HFpEF and to study participation: diagnosis of LVSD, cardio-
myopathy, an EF < 50% regardless of whether diagnosed as
LVSD, or significant cognitive impairment, end of life care,
or New York Heart Association (NYHA) functional class IV.
Variables and data sources
Details on HF register size, numbers screened and excluded by
GPs, and recruitment outcome were collected. Once enrolled,
variables designed to assess risk for, aid diagnosis of, and
subsequently characterize HFpEF were collected. Validated
assessments, standardized equipment, and a Manual of
Operations guided data collection to ensure consistency
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across sites. A detailed protocol for the trans-thoracic
echocardiogram (TTE) based on current European Society of
Cardiology (ESC) guidelines16 was produced to guide
measurement. Standard echocardiogram parameters were
supplemented with global longitudinal strain at one site.
Confirming the diagnosis
Heart failure with preserved ejection fraction diagnosis was
adjudicated by an experienced cardiologist and was based
on self-reported past medical history, assessment at study
visit, clinical information, and TTE interpretation using thresh-
olds specified in the 2016 ESC HF guidelines.16 The ESC
guidelines require the presence of signs and symptoms of
HF, an EF ≥ 50%, elevated levels of natriuretic peptides (NP;
NT-proBNP ≥ 125 pg/mL), and at least one of the following:
relevant structural heart disease (left ventricular hypertrophy
or left atrial enlargement) and/or diastolic dysfunction. Given
that these were ‘treated’ patients on HF registers, patients
were not excluded by study assessed NT-proBNP levels.
Since the study started, two diagnostic algorithms have
been proposed and validated: the H2FPEF score (Figure 1)
and the HFA-PEFF diagnostic algorithm (Figure 2).17,18 The
H2FPEF score, developed and validated by Reddy and
colleagues in 2018, is designed to estimate the likelihood of
HFpEF in patients with unexplained dyspnoea.17 The four-step
HFA-PEFF diagnostic algorithm, conceived in 2019 by the
Heart Failure Association of the ESC, incorporates
advancements in understanding since publication of the
2016 ESC guideline.18 We undertook retrospective evaluation
to compare the study diagnosis of participants with these two
new diagnostic algorithms. The baseline assessment, aligning
with the recommended HFA-PEFF initial work-up, included
12-lead electrocardiogram (ECG), NPs, TTE, and 6 min
walk test.
Statistical analysis
Signs, symptoms, and risk factors for HFpEF were described
using proportions, frequencies, and measures of central ten-
dency appropriate for categorical and continuous variables.
Comparisons were made between participants with and
without clinically adjudicated HFpEF using t-tests, χ2 tests,
and non-parametric methods based on the data. Continuous
variables were assessed for normality with Qplots and the
Shapiro–Wilk test. TTE parameters were compared between
participants with and without HFpEF using these methods.
Final analysis compared the two groups by HFA-PEFF score




Between July 2018 and November 2019, 152 patients from
four sites in England [Cambridge (n = 67), Oxford (n = 64),
Figure 1 H2FPEF score reprinted with the kind permission of Walter Kluwer Health, Inc. HFpEF, heart failure with preserved ejection fraction
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Peterborough (n = 4), and London (n = 17)] were enrolled.
Thirty general practices participated. Across all sites, 2672 re-
cords were screened yielding a potential sample of 881 sub-
jects that were subsequently contacted. Based on the HF
register size and potentially eligible participant list generated
by the automated search, prevalence of possible HFpEF was
0.6% (Cambridge) and 0.3% (Oxford) lower than calculated
prevalence in the population.19 Of the 881 subjects
contacted, 410 responded, 41% of which (n = 171) were pos-
itive responses (Figure 3).
From 171 positive responses, 152 patients attended for
baseline assessments. Ninety-three (61%) were clinically de-
termined to have HFpEF by ESC reference standards.
Although differential diagnosis for participants not meeting
the ESC HFpEF criteria was not planned, the majority of
non-HFpEF participants presented with other HF phenotypes
such as HFrEF (some with recovered EF), hypertrophic
cardiomyopathy, isolated atrial myopathy, or valve disease.
On baseline TTE, 3.4% of participants had an EF < 40%,
11.5% an EF 40–49%, and 85% had an EF ≥ 50%.
Figure 2 HFA-PEFF algorithm for the diagnosis of HFpEF reprinted with the kind permission of John Wiley & Sons, Inc. CT, computed tomography; ECG,
electrocardiogram; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; PET, positron emission tomography
Figure 3 Patient flow chart. HF, heart failure; HFpEF, heart failure with preserved ejection fraction
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Clinical assessment of recruited sample
Clinical information collected as part of the diagnostic
process included assessment of signs, symptoms, and risk
factors for HF (Table 1), corresponding with Stage ‘P’ of the
HFA-PEFF algorithm as seen in Figure 2. The majority of
participants presented with or reported signs and symptoms
of HF. Fatigue/tiredness and exercise intolerance, as assessed
by NYHA class, were the most common followed by breath-
lessness. Breathlessness and fatigue were significantly more
frequent in participants confirmed as HFpEF. The mean age
of the sample was 78.5 years, half had a body mass index
above 30 kg/m2, and most had hypertension. Risk factors
such as chronic kidney disease, diabetes, and atrial fibrillation
(AF) were present in about a third. Overall comorbidity bur-
den was high in the entire cohort by the Charlson Comorbid-
ity Index [median 4, interquartile range (IQR) 3 to 6]. All
participants with confirmed HFpEF had at least one risk factor
for HFpEF, and the diagnosis was significantly more likely in
women and if obesity was present. ECGs indicated that 45%
of participants were in sinus rhythm, 34% in AF, and 21% in
other baseline rhythms (primarily paced), with 15% having
ventricular or supraventricular beats. Inverted t waves
(27%), q waves (14%), ST segment depression (4%), and ST
segment elevation (1.4%) were infrequent.
N-terminal pro-brain natriuretic peptide was not normally
distributed. Removal of one patient who presented with an
extremely elevated level (>18 000 pg/mL) revealed a median
of 314 pg/mL (IQR 124 to 1055). Median values and distribu-
tion of NP levels were not different by presence or absence
of an HFpEF diagnosis (P = 0.841). Seventy-four per cent of
the total sample and 70% of patients with HFpEF had NT-
proBNP levels greater than 125 pg/mL and 44% and 42.5%, re-
spectively, had levels above 400 pg/mL. Patients with AF had a
median NT-proBNP of 855 pg/mL (IQR 255 to 1596) compared
with median 131 pg/mL (IQR 41 to 360) for those in sinus
rhythm (P < 0.001). Twelve patients (six in each group) pre-
sented with NT-proBNP levels of 2000 pg/mL or more.
Echocardiographic analyses revealed few differences
between those with HFpEF and those not meeting criteria. Al-
though EF was slightly higher in those with HFpEF compared
with those without, only mitral valve early diastolic inflow
(MV-E), E/A ratio, and septal e0 were significantly different
between the groups (Table 2). Using the threshold proposed
by the ESC of an E/e0 ratio ≥ 13, patients with confirmed
HFpEF were slightly more likely to meet that criterion than
those without, and similarly with an E/e0 > 15. Using the five
criteria of diastolic dysfunction in the ESC guidelines,16 pa-
tients with HFpEF were significantly more likely to have both
two or more and three or more abnormal diastolic parame-
ters than those without HFpEF. There were no significant
differences between groups in relative wall thickness, pulmo-
nary artery systolic pressures (PASP), and global longitudinal
strain (measured in a subset). Only 76 patients had PASP
documented, but 66% of patients with HFpEF had a level
above 35 mmHg, compared with 44% of those without
(P = 0.071).
Step ‘E’ in the HFA-PEFF algorithm consists of a more de-
tailed comprehensive echocardiogram and NPs if not done
previously. The study TTE protocol was designed to provide
that comprehensive level of assessment, but acquisition
was not possible to achieve in all patients given characteris-
tics such as AF, obesity, and procedure tolerance. However,
consistent with the algorithm, the HFA-PEFF score was








n = 59 P value
Signs and symptoms of heart failure at baseline assessment
Breathlessness/daytime dyspnoea 148 56% 63% 46% 0.035
Orthopnoea 152 22% 22% 25% 0.743
Fatigue/tiredness 152 71% 81% 61% 0.012
Leg oedema 152 45% 46% 43% 0.707
Exercise intolerance 152 0.118
NYHA class I 22% 17% 31%
NYHA class II 57% 62% 48%
NYHA class III 20% 20% 21%
Risk factors
Mean age 152 78.5 (8.6) 79.3 (7.1) 77 (10.5) 0.156
Female sex 152 40% 46% 29% 0.039
Obesity (≥30 kg/m2) 151 50% 57% 39% 0.029
BMI mean 151 30.4 (6.6) 30.9 (6.2) 29.4 (7.1) 0.179
Hypertension 150 79% 81.5% 72% 0.522
Moderate to severe CKD 150 33% 34% 32% 0.789
Diabetes 150 29% 31.5% 26% 0.498
Pulmonary disease 150 29% 31.5% 23% 0.251
Atrial fibrillation 149 34% 32% 39% 0.435
BMI, body mass index; CKD, chronic kidney disease; HFpEF, heart failure with preserved ejection fraction; NYHA, New York Heart
Association.
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calculated in 87 patients who had sufficient data from the ini-
tial analysis to calculate a score in the functional, morpholog-
ical, and biomarker domains.18 Scores were not significantly
different between the two groups when analysed in their
clinically adjudicated category (Table 3).
The HFA-PEFF algorithm proposes that patients with
intermediate scores (2–4) go to Step F1, which includes other
testing such as a stress TTE. This was not part of the study
protocol, so a decision regarding confirmation of HFpEF was
made based on clinical assessment, history, and resting TTE,
as would be common in clinical practice.
Sixty-four patients had full information to calculate the
H2FPEF score.
17 Seventy-two per cent of the patients with
confirmed HFpEF by our assessment had a score of 5 of more
(>80% probability of HFpEF) compared with 59% of the non-
HFpEF group (P = 0.214). About a quarter of both groups had
scores indicative of 50–70% probability of HFpEF. The H2FPEF
score requires assessment of PASP and E/e0, which were not
consistently available in all patients.
Discussion
Key findings
Our study reinforces that finding patients in primary care that
were then confirmed with HFpEF was difficult using HF regis-
ters, due to a lack of identification in general practice. Only
32% of screened patient records with a code for HF had
features suggestive of or consistent with HFpEF, and of those
subsequently enrolled and evaluated, 39% did not have
HFpEF based on assessment against the ESC guidelines. Con-
firmation of HFpEF was challenging using the standard clinical
diagnostic pathways of clinical features, history, and resting
TTE. In general, patients with confirmed HFpEF had higher
rates of specific risk factors for HFpEF (obesity and female
sex), more symptoms (daytime dyspnoea and fatigue), and
specific and cumulative parameters of abnormal diastolic
function than patients without HFpEF.
Although the ESC guidelines provide thresholds for
measures of structural heart disease and diastolic function
considered abnormal, there will be interpretation of the
findings such as how many measures are abnormal, degree
of abnormality, and other components of the echocardio-
gram within the context of the clinical assessment of the
patient. The ESC guidelines in 2016 did not specify how many
measures need to be abnormal, although other guidelines19
state that at least half of five recommended variables of
diastolic function need to be abnormal to diagnose diastolic
dysfunction. Guidelines also differ on exact thresholds for
abnormal results on diastolic dysfunction. Our intent was
not to diagnose patients without HFpEF, but ageing and con-
ditions found such as hypertrophic cardiomyopathy, valvular
Table 2 Echocardiographic parameters
Number of patients HFpEF Non-HFpEF P value
Left ventricular ejection fraction (%) 148 58.1 (7.1) 54.4 (10.8) 0.023
LV mass index, g/m2 147 105.4 (32) 103.1 (32) 0.809
LAVI, mL/m2 124 44.98 (16.5) 50.3 (27.3) 0.178
MV-E, m/s 147 0.85 (.32) 0.97 (.34) 0.046
MV-A, m/s 83 0.86 (.26) 0.75 (.24) 0.068
DecT, m/s 136 218 (71.2) 206 (68.1) 0.349
E/A 81 0.88 (.31) 1.3 (.77) 0.024
Septal e0, cm/s 123 6.2 (1.8) 6.96 (2.1) 0.037
e0 mean sep-lat, cm/s 117 7.75 (2.4) 8.5 (2.3) 0.110
E/e0 mean sep-lat, cm/s 127 12.8 (5.4) 11.6 (5.1) 0.192
E/e0 ≥ 13 125 44% 30% 0.124
E/e0 > 15 125 27% 15% 0.118
IVRT
2 or more abnormal (ESC criteria)
diastolic function parameters
138 69% 36% 0.003
3 or more 32% 23%
RWT 147 0.45 (0.11) 0.44 (0.12) 0.511
GLS 65 16.3 (6.5) 15.4 (5.2) 0.558
PASP 76 39.8 (10.1) 36.2 (11.4) 0.164
DecT, deceleration time; E, early mitral diastolic inflow; E/A, ratio between peak early (E) and late (A) diastolic filling velocities; E/e0, ratio
between early mitral inflow velocity and mitral annular early diastolic velocity; e0, early diastolic tissue velocity; ESC, European Society of
Cardiology; GLS, global longitudinal strain; HFpEF, heart failure with preserved ejection fraction; LAVI, left atrial volume index; LV, left ven-
tricular; MV, mitral valve; PASP, pulmonary artery systolic pressure; RWT, relative wall thickness.





(n = 36) P value




>5 diagnostic of HFpEF 58.2% 44.4%
H2FPEF score HFpEF (n = 50) Non-HFpEF (n = 27) P value
Score 0–2 4% 14.8% 0.214
Score 3–4 26% 24%
Score ≥ 5 72% 59%
HFpEF, heart failure with preserved ejection fraction.
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heart disease, and atrial myopathy can lead to echocardio-
gram abnormalities similar to HFpEF.20–22 Studies evaluating
the performance of HFpEF diagnostic criteria against
haemodynamic evidence or cardiac magnetic resonance
imaging have found limitations in accuracy of
classification.20–22
New recommendations for HFpEF diagnosis have sought to
overcome these limitations, using the HFA-PEFF or H2FPEF
score. However, in this cohort, neither of these scores consis-
tently discriminated between older multi-morbid patients on
HF registers with or without HFpEF. Retrospective application
of the HFA-PEFF algorithm and H2FPEF score was equivocal,
although more patients with HFpEF than without had scores
indicating high probability or considered diagnostic. A sub-
stantial proportion of patients had intermediate scores on
the HFA-PEFF, and confirmation of diagnosis would have re-
quired additional tests, out with our ethical approvals and
funding. In addition, 44% of patients not considered to have
HFpEF in our evaluation had scores considered diagnostic
for HFpEF on the HFA-PEFF, and 59% had scores indicating
high probability on H2FPEF score.
Scores on HFA-PEFF are summed for major (2 points) and
minor (1 point) specific criteria in three categories: functional
(diastolic function parameters and global longitudinal strain),
morphological or structural (left atrial volume, left ventricular
mass, and relative wall thickness), and NPs (thresholds differ
for sinus rhythm and AF). However, only one abnormal find-
ing meeting major criteria in each category is necessary for
maximum points. For example, a patient with one sufficiently
abnormal parameter for diastolic function, left atrial volume
of 34 mL/m2, and an NT-proBNP of 125 pg/mL would have
a score of 5, which could occur in non-HFpEF patients. In a
sample of patients with mixed HF diagnoses, it is not surpris-
ing that some would score highly.
The H2FPEF score gives the greatest weight to two specific
risk factors, AF and obesity, with less emphasis on specific
echocardiographic parameters. The H2FPEF score gives the
most points (3) to the presence of AF, which was found in
39% of our non-HFpEF patients. Clinicians may disagree as
to the differentiation between atrial myopathy due to AF
and HFpEF.18 AF and HFpEF share common pathophysiologic
origins and features, and some postulate AF may indicate the
presence of HFpEF in patients with obesity and diabetes,
while others diagree.18,23 Obesity (given 2 points in the
H2FPEF score) is highly prevalent in most HFpEF cohorts but
was also fairly common (39%) in our non-HFpEF patients.
Thus, a patient with obesity and AF would have a score of 5
(>80% probability of HFpEF) on the H2FPEF score, regardless
of other findings. Ironically because obesity also suppresses
NPs,24 some patients with obesity would not be further
evaluated for HF if NP levels were below threshold values.
The H2FPEF score was derived in a very different population
from our sample, patients with indeterminate dyspnoea after
other cardiac conditions had been ruled out.17
Comparison with other studies
There are a number of potential explanations for why many
people with HFpEF in the community remain undiagnosed
and recruiting patients from primary care for studies in HFpEF
is challenging. Firstly, general practice registers do not hold
sufficient clinical information nor employ specific coding for
HFpEF to enable identification of different HF phenotypes on
their registers.12,13 Cuthbert and colleagues25 and our own re-
search have shown that the proportion of patients included on
a typical practice HF register is much lower than expected
based on epidemiological data26 and that these patients are
more likely to have HFrEF.27 Secondly, our qualitative work
has demonstrated low awareness of HFpEF in primary care.9,28
Lastly, there is variable access to HF specialist services for
non-HFrEF referrals to obtain a definitive diagnosis.7–9
The challenge of HFpEF diagnosis using the standard clini-
cal pathway has been observed in other studies. A study of
patients in the Alberta HEART cohort found that echocardio-
graphic criteria for HFpEF can be fairly common in non-HFpEF
patients and that guideline criteria for diagnosis and adjudi-
cation by experienced clinicians often differ in determination
of HFpEF.21 Imaging with cardiac magnetic resonance has
found patients with hypertrophic cardiomyopathy and con-
strictive pericarditis included in HFpEF cohorts.22 Similar to
our experience, imaging by echocardiogram can be adversely
affected by common comorbidities such as obesity, AF, and
lung disease.22
Implications for practice
This study reinforces findings from our previous research that
patients with HFpEF cannot be readily identified within pri-
mary care HF registers and that guidance and specialist sup-
port is needed to improve diagnosis.12 It also confirms that
HFpEF is a difficult diagnosis to make and can be equivocal
when non-invasive diagnostic criteria are used. Cost and
availability of recommended confirmatory tests will likely
limit their use in many healthcare systems. Diagnostic path-
ways need to be robust when patients present with signs
and symptoms potentially indicating HF. Primary care clini-
cians need greater awareness of HFpEF, its risk factors, and
that neither a normal or near-normal EF nor a lower NT-
proBNP value than the 400 pg/mL threshold proposed by
the UK guidelines29 rule out HFpEF in a patient with clinical
signs and symptoms of HF. Echocardiogram reports should
state clearly whether there is diastolic dysfunction, left ven-
tricular hypertrophy, and increased left atrial volume and that
these factors could indicate HFpEF if EF is ≥50%. Increased
support for diagnosis and management is needed from spe-
cialist services and clear guidance regarding patients with
possible but indeterminate HFpEF when further testing is
not considered appropriate.
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The stepwise approach in HFA-PEFF is intuitively appeal-
ing, as it begins with consideration of risk of HFpEF, signs
and symptoms indicative of HF, and then parameters in do-
mains related to NP testing and echocardiogram. HFA-PEFF
provides alternative major and minor criteria in each do-
main and a more nuanced comprehensive consideration
of the three domains, although not without limitations.
The authors themselves note that it is a limitation to sug-
gest an algorithm can reduce a complex clinical syndrome
to a single diagnosis and that patient mix may affect test
results.18 The initial steps of the HFA-PEFF algorithm could
begin in primary care and be continued for confirmation in
specialist services. Scoring needs to be considered in light
of other factors that can affect test results and evaluation
by a skilled clinician. Decisions about further imaging, stress
testing, and invasive testing in patients with intermediate
risk are likely to be affected by concerns over cost, risk in
frail populations, and value if management unlikely to
change.
An important question when considering the challenges in
diagnosing HFpEF is the utility of a diagnostic label in the
context of limited pharmacological options specific to HFpEF.
However, there are actions that can be taken. Current
recommendations are to manage fluid overload with diuretics
and control comorbid conditions.16 Physical activity has
been shown to improve quality of life and cardiorespiratory
fitness, and intentional weight loss in obese patients may
be beneficial.30,31 Importantly, patients value a clinical
diagnosis,9 and patients with HFpEF can benefit from support
for HF self-management (e.g. monitoring weight and symp-
toms). Furthermore, if lack of evidence-based pharmacologi-
cal therapy undermines the initiative to diagnose HFpEF,
failure to identify patients with HFpEF undermines develop-
ment of the evidence base.
Strengths and limitations
The sample was drawn mainly from primary care (86%) and
represents the types of complex multi-morbid patients with
uncertain HF diagnoses being managed in the community.
The study highlights the lack of consistency in HF clinical cod-
ing and the challenges of diagnosis, which are inevitably influ-
enced by the diagnostic criteria and available testing applied
in the clinical setting. Echocardiograms were reviewed by an
experienced echocardiographer with relevant expertise, and
decisions about HFpEF diagnosis were made by a cardiologist
with specific expertise in HFpEF consistent with usual clinical
practice. This study highlights the importance of improving
identification of HF and HFpEF in primary care and suggests
some strategies that can be used to improve the diagnostic
pathway.
The study has limitations in that the planned sample size
was not reached, and the proportion of sampled patients
found not to have HFpEF was higher than estimated. The
electronic and practice screening process may have intro-
duced selection bias regarding which patients were invited.
Lack of a consistent systematic approach to identification
and screening was a limitation, as this needed to be
conducted by the practices. The search algorithm and inclu-
sion/exclusion criteria were meant to provide a systematic
approach to identification of patients, but practices likely
varied as to their application of criteria, understanding of
HFpEF, and accuracy and completeness of HF registers and
medical records. Data quality when using clinical records will
inevitably be a limitation of observational studies. Although
reasons for screening exclusion were requested, they
were not consistently provided. Reasons recorded were
EF < 50%, valvular heart disease or palliation, frailty syn-
drome, cognitive impairment, and mental illnesses. Lack of
corresponding data on eligible non-participants prevented
assessment of volunteer bias in the cohort, but patients
with more advanced HF or more severe illnesses may have
declined participation. Future studies should develop search
algorithms using codes relating to or suggestive of HF (e.g.
hypertension combined with diuretics) and apply to the
entire register.25 Having searches conducted by someone
with relevant expertise in HFpEF could also improve appro-
priateness of invited patients.
Despite our detailed protocol, not all echocardiograms
were performed at the standard expected, and not all needed
parameters for assessment were available, which limited the
number of patients for whom we could apply HFA-PEFF and
H2FPEF criteria. The criteria were also applied retrospectively
to an older multi-morbid patient group with suspected
HFpEF, which was not the intended approach of the devel-
opers of HFA-PEFF and H2FPEF.
Conclusions
Patients with HFpEF in primary care are difficult to identify,
and greater awareness of the condition among community
clinicians, with clear diagnostic pathways and specialist sup-
port, are needed. Use of diagnostic algorithms and scores
can provide systematic approaches but may be more difficult
to apply in older multi-morbid patients. The diagnostic path-
way should incorporate these systematic approaches to de-
termining HFpEF, beginning in primary care, but driven by
specialist teams taking a greater role in diagnosis and man-
agement of HFpEF. Echocardiogram reports should report
key parameters for assessing cardiac structure and diastolic
function especially when EF is ≥50%. Where diagnostic uncer-
tainty continues, pragmatic decisions will have to be made
regarding the value of additional testing versus management
of presumptive HFpEF.
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